

Table of contents

	Page
National Kidney Registry Personnel	Inside of Front Cover
LSNH Executive Committee	Inside of Front Cover
Scientific Committee	Inside of Front Cover
Table of contents	i
Guide to this Annual Report	ii
List of tables	iii
List of charts	iv
LSNH Presidents' addresses	v
Sponsors	vii
Registry database	x
Opening Section	1
Preface	2
Chapter 1: Introduction	3
Chapter 2: Methods	5
Section I: Fixed Data Modules	9
Chapter 3: Dialysis Centers and Patients / Prevalence of ESRD in Lebanon	10
Chapter 4: Demographics of HD Patients in Lebanon	14
Chapter 5: Dialysis initiation	19
Section II: Monthly Updates Data Modules	27
Chapter 6: Hemodialysis Parameters	28
Chapter 7: Anemia	32
Chapter 8: Mineral & Molecular Balance	37
Chapter 9: Vital signs and anthropometrics	42
Chapter 10: Medications	46
Chapter 11: Clinical outcomes and complications	50
Appendices	53
I. Reference tables	54
II. Performance Measures to be Monitored	74
III. Research program: Overview	77
First Study: Vascular Access	78
Second Study: Dedicated Dietitian	82
National Kidney Registry Operation	Inside of Back Cover
Contacts	Inside of Back Cover

List of Tables

Title	Page
<u>Reference Tables</u>	
Table3.1 Hospital-based HD centers in Lebanon / registry participation & analysis eligibility	54
Table4.1 Age patterns of HD patients in Lebanon by patient type and region (%)	56
Table4.2 Demographic profile of HD patients in Lebanon by patient type and region (%)	57
Table4.3 Risk profile of HD patients in Lebanon by patient type and region (%)	58
Table 5.1 Clinical profile at dialysis initiation by patient type and region	59
Table 5.2 Vital signs of HD patients in Lebanon at their first dialysis session (all patients)	60
Table 5.3 Laboratory readings in HD patients in Lebanon at time of their first dialysis session by patient type	60
Table 5.4 Anemia laboratory readings in HD patients at time of their first dialysis session by patient type and region	61
Table 5.5 Levels of select mineral & molecular laboratory readings in HD patients in Lebanon at time of their first dialysis session by patient category and region	61
Table 5.6 Patients' use of erythropoietin stimulating agents or iron prior to start of HD (%)	61
Table 5.7 HD patients with prior transplant: graft profile & treatment	62
Table 6.1 Dialysis session practices in HD patients in Lebanon	63
Table6.2 Vascular access complications in HD patients in Lebanon	64
Table6.3 Dialysis adequacy parameters in HD patients in Lebanon by case type & region (%)	65
Table7.1 Anemia management parameters in HD patients in Lebanon by patient type & region (%)	66
Table7.2 Dosing patterns of Erythropoietin and iron use by HD patients in Lebanon overall and by region	67
Table 7.3 Use of Erythropoietin and iron by HD patients in Lebanon by patient type and region (%)	67
Table8.1 Mineral balance parameters in HD patients in Lebanon by patient type & region (%)	68
Table8.2 Molecular balance parameters in HD patients in Lebanon by patient type & region (%)	69
Table9.1 Vital signs in HD patients in Lebanon by patient type & region (%)	70
Table9.2 Anthropometric parameters in HD patients in Lebanon by patient type & region (%)	71
Table 10.1. Use of medications by HD patients in Lebanon overall and by region	72
Table11.1 Outcomes of HD patients in Lebanon by patient type and region (%)	73
<u>Chapter Tables</u>	
Table 2.1 Data deletions and transformations used in key parameters	7
Table 3.2 Number of dialysis units, patients, mortalities and patient-months in this report by patient status and region, as of November 15, 2012	13
Table 5.8 Profile of key anemia parameters at onset of HD among incident and prevalent patients	21
Table 5.9 Profile of key molecular chemistry parameters at onset of HD among incident and prevalent Patients	22
Table 5.10 Levels of eGFR at onset of HD among incident and prevalent patients and by Region	24
Table 5.11 Profile of key mineral chemistry parameters at onset of HD among incident and prevalent patients	24
Table 7.4 Frequency(%) of testing iron parameters overall, and ferritin by region	33
Table 7.5 Frequency (%) of testing ferritin by type of coverage among HD patients in Lebanon	33
Table 7.6 Distribution of patient-months of TSAT levels among HD patients into ranges by region	34
Table 7.7 Distribution of patient-months of TSAT levels among HD patients into ranges by region	35
Table 7.8 Proportion of patient-months by type of EPO used by region (%)	35
Table 7.9 Proportion of patient-months of ESA use and weekly dose by hemoglobin level	36
Table 7.10 Dose of IV iron by levels of hemoglobin and ferritin	36
Table 7.11 Dose of IV iron and ferritin levels by frequency of ferritin testing	36
Table 10.2 Distribution of hypertensive HD patients by reporting source	47
Table 10.3 Distribution of diabetic HD patients by insulin dependency and reporting source	47
Table 10.4 Proportion of diabetic patients and their insulin dependency at baseline	48
Table 10.5 Distribution of HD patients with cardiac disease by reporting source	48
Table 11.2 Distribution of reported mortality by patient type and region	50
Table 11.3 Emergent complications frequency count of patients and events and their % of total	52

List of Figures

Title	Page
Figure 3.1 Changes in prevalence of ESRD in Lebanon and international	10
Figure 3.2 Distribution of HD units in Lebanon by region	11
Figure 3.3 Distribution of HD patients in Lebanon by region	11
Figure 3.4 Hemodialysis Units in Lebanon and their patient count (November 30, 2012)	12
Figure 4.1 Ages of HD patients in Lebanon at start of dialysis: by region and patient category	14
Figure 4.2 Age of HD patients in Lebanon on June 2, 2012 (data cutoff date): by region and patient category	15
Figure 4.3 Ages of HD patients in Lebanon at mortality: by region and patient category	15
Figure 4.4 Distribution of HD patients gender in Lebanon: by region and patient category	16
Figure 4.5 Distribution of HD patients by level of education: by region and gender	16
Figure 4.6 Distribution of HD patients into payer coverage: by patient category, gender and region	17
Figure 5.1 Distribution of HD patients into cause of ESRD, by patient category, gender and region	19
Figure 5.2 Distribution of HD patients by body mass index levels, by region and patient category	20
Figure 5.3 Distribution of patients at onset of HD by Hb level and by patient type and region	21
Figure 5.4 Distribution of patients at onset of HD by Ferritin levels and region	22
Figure 5.5 Distribution of patients at onset of HD by Albumin levels and by region and patient type	23
Figure 5.6 Distribution of patients at onset of HD by Creatinine levels by region and patient type	23
Figure 5.7 Distribution of patients at onset of HD by calcium and phosphorous values by Region	25
Figure 5.8 Distribution of patients by type of first vascular access constructed by region	25
Figure 5.9 Distribution of patients by type of vascular access used in first HD session by region	26
Figure 6.1 Distribution of HD patients in Lebanon by how long on dialysis by region	28
Figure 6.2 Distribution of patients by how long on dialysis, overall and by region	29
Figure 6.3 Distribution of patients by type of observed vascular access complications	30
Figure 6.4 Distribution of patients by type of observed vascular access repairs done	30
Figure 6.5 Distribution of HD patient by Kt/V level and patient category	31
Figure 7.1 Distribution of Hb levels in HD patients in Lebanon by region and patient category	32
Figure 7.2 Distribution of % patient-months of Hb level ranges in HD patients by region of Lebanon	33
Figure 7.3 Distribution of ferritin levels in HD patients in Lebanon by region and patient category	34
Figure 8.1 Distribution of patient-month levels of serum calcium by region and patient category	37
Figure 8.2 Distribution of patient-month levels of serum phosphorous by region and patient category	38
Figure 8.3 Distribution of patient-month levels of serum potassium by region and patient category	38
Figure 8.4 Distribution of patient-month levels of albumin by region and patient category	39
Figure 8.5 Distribution of HD patients by albumin levels by region	39
Figure 8.6 Distribution of patient-month levels of iPTH by region and patient category	40
Figure 8.7 Distribution of HD patients by iPTH levels by region	40
Figure 8.8 Types of phosphate binders used in Lebanon by region	41
Figure 9.1 Distribution of BMI levels by region	43
Figure 9.2 BMI levels in patients undergoing maintenance HD, by patient type, gender and region	44
Figure 9.3 Distribution of waist circumference levels by Region	45
Figure 9.4 Distribution of percent body fat levels by region and patient category	45